- Participant’s age ≥18 years (or the minimum country specific age of consent if >18) at Visit 1 (Screening).
- Diagnosis of MM as defined according to IMWG criteria (Rajkumar et al, 2014), including measurable disease based on IMWG criteria as defined by at least 1 of the following (as assessed by the central laboratory for Part 2):
- Serum M-protein ≥0.5 g/dL (Part 1) and ≥1 g/dL (Part 2);
- Urinary M-protein excretion ≥200 mg/24 hours;
- Involved FLC ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio (<0.26 or >1.65).
- Part 2 only: Participant has NDMM and is transplant-ineligible. In Part 2, transplant ineligible is defined as:
- Participants not considered candidates for high-dose chemotherapy and ASCT due to age or
- Participants with important comorbidities likely to have a negative impact on tolerability of high dose chemotherapy and ASCT.
- ECOG performance status ≤2.
- BM function characterized by the following:
- ANC ≥1.0 × 109/L without G-CSF support at least 7 days prior to screening sample);
- Platelet count ≥75,000/μL if <50% of BM nucleated cells are plasma cells, or ≥50,000/μL if ≥50% of BM nucleated cells are plasma cells (without transfusion support at least 7 days prior to screening sample); and
- Hemoglobin ≥8 g/dL (without transfusion support at least 14 days prior to screening sample).
NOTE: Hematologic parameters are also to be met on Day 1 prior to proceeding with study treatment administration.
- Corrected serum calcium ≤14 mg/dL (≤3.5 mmol/L), or free ionized calcium ≤6.5 mg/dL (≤1.6 mmol/L).
- Smoldering MM or MGUS or Waldenström’s Macroglobulinemia or Plasma cell leukemia defined as ≥20% circulating plasma cells in the peripheral blood with an absolute plasma cell count of more than 2 × 109/L, or Systemic light chain amyloidosis, or POEMS Syndrome.
- Impaired cardiovascular function or clinically significant cardiovascular diseases, defined as any of the following within 6 months prior to enrollment:
- Acute myocardial infarction or acute coronary syndromes (eg, unstable angina, coronary artery bypass graft, coronary angioplasty or stenting, symptomatic pericardial effusion);
- Clinically significant cardiac arrhythmias (eg, uncontrolled atrial fibrillation or uncontrolled paroxysmal supraventricular tachycardia);
- Thromboembolic or cerebrovascular events (eg, transient ischemic attack, cerebrovascular accident, deep vein thrombosis [unless associated with a central venous access complication] or pulmonary embolism);
- Prolonged QT syndrome (or QTcF >470 msec at screening)
- LVEF <40% as determined by a MUGA scan or ECHO at screening.
- Ongoing Grade 3 (Part 1)/Grade 2 (Part 2) or higher peripheral sensory or motor neuropathy, history of GBS or GBS variants, or history of any Grade >3 (Part 1)/Grade >2 (Part 2) peripheral motor polyneuropathy.
- Participants with active, uncontrolled bacterial, fungal, or viral infection, including (but not limited to) COVID-19/SARS-CoV-2, HBV, HCV, and known HIV or AIDS-related illness. Active infections must be resolved at least 21 days prior to enrollment. Participants treated with systemic therapeutic anti-infective agents within 28 days prior to enrollment are not eligible. Prophylactic use of systemic anti-infective agents is permitted. Comments regarding specific circumstances follow:
- COVID-19/SARS-CoV-2: SARS-CoV-2 PCR testing is mandated within 5 days prior to randomization. If a participant has a positive PCR test result for SARS-CoV-2 infection within 5 days prior to randomization, is known to have asymptomatic infection or is suspected of having SARS-CoV-2, they are excluded.
- HIV: In equivocal cases, participants whose viral load is negative may be eligible. HIV seropositive participants who are otherwise healthy and at low risk for AIDS-related outcomes could be considered eligible. Potential eligibility for a specific HIV positive protocol candidate should be evaluated and discussed with the Sponsor prior to any screening, based on current and past CD4 and T-cell counts, history (if any) of AIDS defining conditions (eg, opportunistic infections), and status of HIV treatment. Also, the potential for drug-drug interactions will be taken into consideration.
- HBV/HCV: Relevant laboratory tests should be performed at screening. Refer to CDC website (https://www.cdc.gov/hepatitis/index.htm) for further details.
- HBV:
- This criterion excludes participants with a positive HBsAg (ie, either acute or chronic active hepatitis).
- However, participants with HBV antibody positivity indicating immunity, either due to vaccination or prior natural infection, are eligible.
- Participants with positive anti-HBcAb but negative HBsAg and anti-HBsAb profile are eligible if HBV DNA is not detected.
- HCV: Positive HCV antibody is indicative of infection but may not necessarily render a potential participant ineligible, depending on clinical circumstances. If exposure to HCV is recent, HCV antibody may not have yet turned positive. In this circumstance it is recommended to test HCV RNA. Refer to CDC website for further details (https://www.cdc.gov/hepatitis/hcv/pdfs/hcv_graph.pdf).
- Lung imaging is required within 7 days (Part 1) or 14 days (Part 2) prior to randomization (See SoA). Participants with radiologic signs consistent with active respiratory infection are excluded.
- Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, carcinoma in situ, or Stage 0/1 with minimal risk of recurrence per investigator.
- Participants with known or suspected hypersensitivity to the study interventions or any of their excipients.
- Participants with known or suspected CNS or clinical signs of myelomatous meningeal involvement.
- Other surgical (including major surgery within 14 days prior to enrollment), medical or psychiatric conditions including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator’s judgment, make the participant inappropriate for the study.
- Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease or previous gastric resection or lap band surgery that may significantly alter the absorption of oral drugs. Gastroesophageal reflux disease under treatment with proton pump inhibitors is allowed (assuming no drug interaction potential).
- Participants who are unable to tolerate lenalidomide, daratumumab, or control arm study interventions (Part 2 only), or discontinued prior lenalidomide or daratumumab due to treatment-related toxicity (Part 1 only).
- Previous systemic treatment for MM except for a short course of corticosteroids (ie, total of 160 mg dexamethasone or equivalent before the first dose of study intervention). A cumulative dose of systemic corticosteroids equivalent to ≥20 mg of dexamethasone during screening.
- Live attenuated vaccine administered within 4 weeks of the first dose of study intervention.
- Administration of investigational product (eg, drug or vaccine) concurrent with study intervention or within 30 days (or as determined by the local requirement) preceding the first dose of study intervention used in this study. A participant may be eligible if they are in the follow-up phase of an investigational study if they meet the criterion for time elapsed from previous administration of investigational product. Cases must be discussed with Sponsor’s medical monitor to judge eligibility.
- Hepatic and renal function characterized by the following:
- Total bilirubin >1.5 × ULN (>3 × ULN if documented Gilbert’s syndrome);
- AST >2.5 × ULN and ALT >2.5 × ULN.
- Part 2 only (NDMM population): Renal function defined according to local institutional standard method: eGFR <30 mL/min/1.73 m2 using the 2021 CKD-EPI Creatinine Equation* or estimated CrCl <30 mL/min using Cockcroft Gault formula. If both formulae are calculated, the higher of the two values may be used. A 24-hour urine collection for CrCl may also be used in equivocal cases where amyloidosis is suspected.
*https://www.kidney.org/content/ckd-epi-creatinine-equation-2021
14 . Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and Sponsor and Sponsor delegate employees directly involved in the conduct of the study, and their respective family members.
CIUSSS de l’Estrie – CHUS
CIUSSS de l’Est-de-L’Île-de-Montréal – Hôpital Maisonneuve-Rosemont